Exploration of Neuroprotective Therapy

Table 2. The contribution of multifunction induced by 10 ACs alone or in mixture to BPSDS via two normalization formulae calculations in H₂O₂-treated ECs.

Group/Formula		NO (μmol/L)	eNOS (μmol/L)	ROS (μmol/L)
Sham (S)		22.30 ± 0.22	37.20 ± 1.19	2,433.60 ± 41.88
Vehicle (V)		11.00 ± 0.52	17.53 ± 1.36	20,432.47 ± 411.95
BPSDS		20.76 ± 1.11	33.76 ± 2.26	7,652.73 ± 65.49
Contribution rate from 2 formulae	10 ACs	19.24 ± 1.39	29.52 ± 2.66	11,911.43 ± 70.90
	Formula 1 (%)	92.68	87.44	155.64
	Formula 2 (%)	97.78	88.19	86.16
	Hesperidin	23.50 ± 1.37	38.99 ± 1.07	2,804.47 ± 21.27
	F1	113.20	115.49	114.6
	F2	113.01	114.57	115.75
	Saikosaponin A	21.14 ± 1.81	41.18 ± 0.86	4,279.00 ± 126.90
	F1	101.83	121.98	55.91
	F2	101.80	120.67	110.96
	Tangeretin	20.55 ± 1.52	32.08 ± 1.25	5,904.83 ± 1.53
	F1	98.99	95.02	77.16
	F2	99.00	95.32	105.68
	Glycyrrhetinic acid	17.67 ± 0.88	29.39 ± 0.86	6,091.07 ± 58.66
	F1	85.12	87.06	79.59
	F2	85.33	87.83	105.07
	Albiflorin	15.59 ± 0.2	25.71 ± 0.86	6,433.73 ± 50.45
	F1	75.10	76.16	84.07
	F2	75.45	77.58	103.96
	Meranzin hydrate	18.13 ± 0.23	24.00 ± 0.11	11,328.17 ± 174.61
	F1	87.33	71.09	148.03
	F2	87.51	72.81	88.06
	Ferulic acid	16.96 ± 0.41	23.61 ± 0.71	15,090.63 ± 188.99
	F1	81.70	69.93	197.19
	F2	81.96	71.73	75.83
	Nobiletin	14.38 ± 1.24	21.09 ± 0.94	8,709.77 ± 70.91
	F1	69.27	62.47	113.81
	F2	69.71	64.71	96.57
	Naringin	12.91 ± 0.26	20.40 ± 1.09	10,501.00 ± 281.40
	F1	62.19	60.43	137.22
	F2	62.73	62.79	90.75
	Glycyrrhizic acid	8.75 ± 1.38	11.71 ± 0.51	12,978.40 ± 146.39
	F1	42.75	34.69	169.59
	F2	42.97	38.58	82.7

Return to article view

Formula 1: ACs/BPSDS; Formula 2: [(ACs – V) – (V – S)]/[(BPSDS or BSS – V) – (V – S)]. BSS: Bupleurum chinense Shugan-San; ECs: endothelial cells; eNOS: endothelial nitric oxide.

Supplementary materials

The supplementary materials for this article are available at: https://www.explorationpub.com/uploads/Article/file/1004159_sup_1.pdf.

Declarations

Author contributions

XH: Conceptualization, Resources, Writing—original draft, Writing—review & editing. RZ: Writing—review & editing, Writing—original draft, Methodology, Investigation, Formal analysis, Data curation. CX: Software, Formal analysis, Data curation. HQ: Investigation, Formal analysis, Data curation. YH: Investigation, Formal analysis, Data curation. ZG and QZ: Formal analysis, Data curation. MX, SS, AY, JZ, YL, and CS: Validation, Resources, Data curation. PR: Methodology, Investigation. All authors read and approved the submitted version.

Conflicts of interest

All authors declare that they have no known conflict of interest or personal relationships that could have appeared to influence the work reported in this paper.

Ethical approval

All animals in this experiment complied with the ethical rules for experimental animals of Nanjing University of Traditional Chinese Medicine (Number: 201912A008).

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The datasets supporting the findings of this study are available from the corresponding author upon reasonable request.

Funding

Our Research Project was fully supported by the National Natural Science Foundation of China (Grant Nos. 81973589, 81573797, and 81872967). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Huang X, Qin F, Zhang HM, Xiao HB, Wang LX, Zhang XY, et al. Cardioprotection by Guanxin II in rats with acute myocardial infarction is related to its three compounds. J Ethnopharmacol. 2009;121:268–73. [DOI] [PubMed]

Huang X, Fan R, Zhang H, Ren P, Qing F, Wang Y. Bioethnopharmaceutical analytical pharmacology: a strategy for elucidating ethnoherbal absorbed bioactive compounds. Chin Tradit Herb Drugs. 2010;41:337–9.

Shi S, Yan H, Chen Y, Liu Y, Zhang X, Xie Y, et al. Pharmacokinetic study of precisely representative antidepressant, prokinetic, anti-inflammatory and anti-oxidative compounds from Fructus aurantii and Magnolia Bark. Chem Biol Interact. 2020;315:108851. [DOI] [PubMed]

Huang X, Zhao Q, Xia L, Shi S. Letter to the Editor in response to the articles 'Lianhuaqingwen exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2)' and 'Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.'. Pharmacol Res. 2021;163:105289. [DOI] [PubMed] [PMC]

Huang Y, Xu M, Li J, Chen K, Xia L, Wang W, et al. Ex vivo to in vivo extrapolation of syringic acid and ferulic acid as grape juice proxies for endothelium-dependent vasodilation: Redefining vasoprotective resveratrol of the French paradox. Food Chem. 2021;363:130323. [DOI] [PubMed]

Zhang YJ, Huang X, Wang Y, Xie Y, Qiu XJ, Ren P, et al. Ferulic acid-induced anti-depression and prokinetics similar to Chaihu-Shugan-San via polypharmacology. Brain Res Bull. 2011;86:222–8. [DOI] [PubMed]

Zhang YJ, Huang W, Huang X, Wang Y, Wang Z, Wang C, et al. Fructus Aurantii induced antidepressant effect via its monoaminergic mechanism and prokinetic action in rat. Phytomedicine. 2012;19:1101–7. [DOI] [PubMed]

Xie Y, Huang X, Hu SY, Qiu XJ, Zhang YJ, Ren P, et al. Meranzin hydrate exhibits anti-depressive and prokinetic-like effects through regulation of the shared α2-adrenoceptor in the brain-gut axis of rats in the forced swimming test. Neuropharmacology. 2013;67:318–25. [DOI] [PubMed]

Mu DZ, Xue M, Xu JJ, Hu Y, Chen Y, Ren P, et al. Antidepression and Prokinetic Effects of Paeoniflorin on Rats in the Forced Swimming Test via Polypharmacology. Evid Based Complement Alternat Med. 2020;2020:2153571. [DOI] [PubMed] [PMC]

10.

Liu YL, Xu JJ, Han LR, Liu XF, Lin MH, Wang Y, et al. Meranzin Hydrate Improves Depression-Like Behaviors and Hypomotility via Ghrelin and Neurocircuitry. Chin J Integr Med. 2023;29:490–9. [DOI] [PubMed]

11.

Luo M, Huang X, Wang Y, Ren P. Zhiqiaochuanxiong decoction for major depressive disorder complicated by functional dyspepsia: a case report with fast-acting efficacy. J Tradit Chin Med. 2015;35:697–702. [DOI] [PubMed]

12.

Zhou RZ, Xu CD, Qian HT, Huang X. Ex vivo to in vivo extrapolation of primary absorbed compounds as multifunctional proxies of Zhiqiao (Fructus Aurantii Submaturus)-Houpo (Cortex Magnoliae Officinalis) herb pair. J Tradit Chin Med. 2026;46:51–61. [DOI] [PubMed]

13.

Liu Y, Wang W, Chen Y, Yan H, Wu D, Xu J, et al. Simultaneous quantification of nine components in the plasma of depressed rats after oral administration of Chaihu-Shugan-San by ultra-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry and its application to pharmacokinetic studies. J Pharm Biomed Anal. 2020;186:113310. [DOI] [PubMed]

14.

Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol. 1978;47:379–91. [DOI] [PubMed]

15.

De Winter BY, Bredenoord AJ, De Man JG, Moreels TG, Herman AG, Pelckmans PA. Effect of inhibition of inducible nitric oxide synthase and guanylyl cyclase on endotoxin-induced delay in gastric emptying and intestinal transit in mice. Shock. 2002;18:125–31. [DOI] [PubMed]

16.

Liu X, Luo M, Wang Z, Yang SJ, Su M, Wang Y, et al. Mind shift I: Fructus Aurantii - Rhizoma Chuanxiong synergistically anchors stress-induced depression-like behaviours and gastrointestinal dysmotility cluster by regulating psycho-immune-neuroendocrine network. Phytomedicine. 2024;128:155324. [DOI] [PubMed]

17.

Zhao Q, Liu J, Chen L, Gao Z, Lin M, Wang Y, et al. Phytomedicine Fructus Aurantii-derived two absorbed compounds unlock antidepressant and prokinetic multi-functions via modulating 5-HT3/GHSR. J Ethnopharmacol. 2024;323:117703. [DOI] [PubMed]

18.

Fujitsuka N, Asakawa A, Hayashi M, Sameshima M, Amitani H, Kojima S, et al. Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin. Biol Psychiatry. 2009;65:748–59. [DOI] [PubMed]

19.

Gastaldon C, Raschi E, Kane JM, Barbui C, Schoretsanitis G. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. Psychother Psychosom. 2021;90:41–8. [DOI] [PubMed]

20.

Chancellor D. The depression market. Nat Rev Drug Discov. 2011;10:809–10. [DOI] [PubMed]

21.

Hawkins MA, Callahan CM, Stump TE, Stewart JC. Depressive symptom clusters as predictors of incident coronary artery disease: a 15-year prospective study. Psychosom Med. 2014;76:38–43. [DOI] [PubMed] [PMC]

22.

Afridi MI, Siddiqui MA, Ansari A. Gastrointestinal somatization in males and females with depressive disorder. J Pak Med Assoc. 2009;59:675–9. [PubMed]

23.

Norton J, Pastore M, Ancelin M, Hotopf M, Tylee A, Mann A, et al. Time-dependent cognitive and somatic symptoms of depression as predictors of new cardiac-related events in at-risk patients: the UPBEAT-UK cohort. Psychol Med. 2021;51:1271–8. [DOI] [PubMed]

24.

Bracken RM, Linnane DM, Brooks S. Plasma catecholamine and nephrine responses to brief intermittent maximal intensity exercise. Amino Acids. 2009;36:209–17. [DOI] [PubMed]

25.

Stockhorst U, Antov MI. Modulation of Fear Extinction by Stress, Stress Hormones and Estradiol: A Review. Front Behav Neurosci. 2016;9:359. [DOI] [PubMed] [PMC]

26.

Ning B, Wei Y, Luo C, Yang L, Zheng Z, Fang P, et al. Natural products targeting the gut-brain axis for the treatment of post-cardiac procedures anxiety or depression. Phytomedicine. 2026;155:158061. [DOI] [PubMed]

27.

Carney RM, Freedland KE. Depression and coronary heart disease. Nat Rev Cardiol. 2017;14:145–55. [DOI] [PubMed]

28.

Edmondson D, Newman JD, Whang W, Davidson KW. Emotional triggers in myocardial infarction: do they matter? Eur Heart J. 2013;34:300–6. [DOI] [PubMed] [PMC]

29.

Li L, Yu AL, Wang ZL, Chen K, Zheng W, Zhou JJ, et al. Chaihu-Shugan-San and absorbed meranzin hydrate induce anti-atherosclerosis and behavioral improvements in high-fat diet ApoE-/- mice via anti-inflammatory and BDNF-TrkB pathway. Biomed Pharmacother. 2019;115:108893. [DOI] [PubMed]

30.

Yin X, Guven N, Dietis N. Stress-based animal models of depression: Do we actually know what we are doing? Brain Res. 2016;1652:30–42. [DOI] [PubMed]

31.

Kennedy CLM, Carter SD, Mifsud KR, Reul JMHM. Unexpected effects of metyrapone on corticosteroid receptor interaction with the genome and subsequent gene transcription in the hippocampus of male rats. J Neuroendocrinol. 2020;32:e12820. [DOI] [PubMed]

32.

Trunnell ER, Carvalho C. The forced swim test has poor accuracy for identifying novel antidepressants. Drug Discov Today. 2021;26:2898–904. [DOI] [PubMed]

33.

Gururajan A, Reif A, Cryan JF, Slattery DA. The future of rodent models in depression research. Nat Rev Neurosci. 2019;20:686–701. [DOI] [PubMed]

34.

Reardon S. Rodent tests for psychiatric drugs get a rethink. Science. 2024;383:1279. [DOI] [PubMed]

35.

Gagliano G, Monteverdi A, Casali S, Laforenza U, Gandini Wheeler-Kingshott CAM, D'Angelo E, et al. Non-Linear Frequency Dependence of Neurovascular Coupling in the Cerebellar Cortex Implies Vasodilation-Vasoconstriction Competition. Cells. 2022;11:1047. [DOI] [PubMed] [PMC]

36.

Huang W, Huang X, Xing Z, Qiu X, Wang Y, Fan R, et al. Meranzin hydrate induces similar effect to Fructus Aurantii on intestinal motility through activation of H1 histamine receptors. J Gastrointest Surg. 2011;15:87–96. [DOI] [PubMed]

37.

Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci. 2008;105:4826–31. [DOI]

38.

Salewskij K, Penninger JM. Blood Vessel Organoids for Development and Disease. Circ Res. 2023;132:498–510. [DOI] [PubMed]

39.

König P, Dedio J, Müller-Esterl W, Kummer W. Distribution of the novel eNOS-interacting protein NOSIP in the liver, pancreas, and gastrointestinal tract of the rat. Gastroenterology. 2002;123:314–24. [DOI] [PubMed]

40.

Schaum N, Lehallier B, Hahn O, Pálovics R, Hosseinzadeh S, Lee SE, et al.; Tabula Muris Consortium; Pisco AO, Karkanias J, Neff NF, Keller A, Darmanis S, Quake SR, et al. Ageing hallmarks exhibit organ-specific temporal signatures. Nature. 2020;583:596–602. [DOI] [PubMed] [PMC]

41.

Codarri Deak L, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature. 2022;610:161–72. [DOI] [PubMed] [PMC]

42.

Despic V, Jaffrey SR. mRNA ageing shapes the Cap2 methylome in mammalian mRNA. Nature. 2023;614:358–66. [DOI] [PubMed] [PMC]

43.

Kubota K, Yokoyama M, Onitsuka K, Kanemura N. The investigation of an analysis method for co-activation of knee osteoarthritis utilizing normalization of peak dynamic method. Gait Posture. 2023;101:48–54. [DOI] [PubMed]

44.

Han M, Zeng D, Tan W, Chen X, Bai S, Wu Q, et al. Brain region-specific roles of brain-derived neurotrophic factor in social stress-induced depressive-like behavior. Neural Regen Res. 2025;20:159–73. [DOI] [PubMed] [PMC]

45.

Vaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M, et al.; ESC Scientific Document Group Reviewers. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2020;41:1687–96. [DOI] [PubMed] [PMC]

46.

Greaney JL, Saunders EFH, Santhanam L, Alexander LM. Oxidative Stress Contributes to Microvascular Endothelial Dysfunction in Men and Women With Major Depressive Disorder. Circ Res. 2019;124:564–74. [DOI] [PubMed] [PMC]

47.

Stone LA, Harmatz ES, Goosens KA. Ghrelin as a Stress Hormone: Implications for Psychiatric Illness. Biol Psychiatry. 2020;88:531–40. [DOI]

48.

Elantary R, Othman S. Role of L-carnitine in Cardiovascular Health: Literature Review. Cureus. 2024;16:e70279. [DOI]

49.

Wang Z, Wu F, Zhou Q, Qiu Y, Zhang J, Tu Q, et al. Berberine Improves Vascular Dysfunction by Inhibiting Trimethylamine-N-oxide via Regulating the Gut Microbiota in Angiotensin II-Induced Hypertensive Mice. Front Microbiol. 2022;13:814855. [DOI] [PubMed] [PMC]

50.

Xie A, Ensink E, Li P, Gordevičius J, Marshall LL, George S, et al. Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms. Mov Disord. 2022;37:1644–53. [DOI] [PubMed] [PMC]

51.

Procházková N, Falony G, Dragsted LO, Licht TR, Raes J, Roager HM. Advancing human gut microbiota research by considering gut transit time. Gut. 2023;72:180–91. [DOI] [PubMed] [PMC]

52.

Llorens-Martín M, Jurado-Arjona J, Bolós M, Pallas-Bazarra N, Ávila J. Forced swimming sabotages the morphological and synaptic maturation of newborn granule neurons and triggers a unique pro-inflammatory milieu in the hippocampus. Brain Behav Immun. 2016;53:242–54. [DOI] [PubMed]

53.

Musazzi L, Tornese P, Sala N, Popoli M. Acute or Chronic? A Stressful Question. Trends Neurosci. 2017;40:525–35. [DOI] [PubMed]

54.

Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, et al. Ghrelin. Mol Metab. 2015;4:437–60. [DOI] [PubMed] [PMC]

55.

Whitty CJM, Watt FM. Map clusters of diseases to tackle multimorbidity. Nature. 2020;579:494–6. [DOI] [PubMed]

56.

Pietzner M, Stewart ID, Raffler J, Khaw KT, Michelotti GA, Kastenmüller G, et al. Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med. 2021;27:471–9. [DOI] [PubMed] [PMC]

57.

Whitney DG, Schmidt M, Hurvitz EA. Shared Physiologic Pathways Among Comorbidities for Adults With Cerebral Palsy. Front Neurol. 2021;12:742179. [DOI] [PubMed] [PMC]

58.

Shabir O, Moll TA, Matuszyk MM, Eyre B, Dake MD, Berwick J, et al. Preclinical models of disease and multimorbidity with focus upon cardiovascular disease and dementia. Mech Ageing Dev. 2020;192:111361. [DOI] [PubMed]

59.

Claypool AL, Goldhaber-Fiebert JD, Brandeau ML. Assessing Interventions That Prevent Multiple Infectious Diseases: Simple Methods for Multidisease Modeling. Med Decis Making. 2022;42:436–49. [DOI] [PubMed] [PMC]

60.

Desdín-Micó G, Soto-Heredero G, Aranda JF, Oller J, Carrasco E, Gabandé-Rodríguez E, et al. T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. Science. 2020;368:1371–6. [DOI] [PubMed] [PMC]

61.

Skou ST, Mair FS, Fortin M, Guthrie B, Nunes BP, Miranda JJ, et al. Multimorbidity. Nat Rev Dis Primers. 2022;8:48. [DOI]

62.

Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554:317–22. [DOI] [PubMed]